NWBOW Profile
Northwest
Biotherapeutics, Inc., trading under the ticker symbol NWBO, was a
biotechnology company that developed immunotherapy treatments for
cancer. The company was headquartered in Bethesda, Maryland.
Northwest Biotherapeutics' lead product candidate was DCVax, a
personalized immune therapy that was being developed for the treatment
of various types of cancer, including brain cancer and ovarian cancer.
The company also had other product candidates in its pipeline that
were being developed for the treatment of various cancers.
In
2019, Northwest Biotherapeutics filed for bankruptcy, and the company
was delisted from the NASDAQ stock exchange.
Prior to its
bankruptcy, as of its most recent financial filings, Northwest
Biotherapeutics had a market capitalization of approximately $32
million and employed over 50 professionals across its various
operations worldwide. The company faced challenges in securing funding
for its research and development activities and in successfully
completing clinical trials for its product candidates.
Investors who held NWBO stock may have lost their investment as a
result of the bankruptcy. Investors who are interested in the
biotechnology industry may want to research other publicly traded
companies in the sector, evaluate their financial performance,
competitive position, and growth prospects. The biotechnology industry
is highly competitive, and the success of a company's research and
development activities is
|
